Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Liquidia entered a global settlement with United Therapeutics resolving all six pending lawsuits, ensuring YUTREPIA remains available to PAH patients without disruption. Liquidia will pay a net $380.7 million: $175 million within 30 business days, plus $145.4 million in two 2027 installments and $60.3 million related to the antitrust litigation. The company is also dropping its PH-ILD label and promotion of YUTREPIA following the adverse Delaware patent ruling. The company disclosed preliminary Q3 2026 YUTREPIA net sales of $222.7 million and $396.1 million in cash as of September 30, 2026, and says it can fund the settlement and pipeline without new financing.
Key figures
- Revenue
- 222700000
- Guidance
- Funding settlement payments from YUTREPIA sales and cash on hand; expects to rebuild cash and fund clinical studies without additional financing
- Initial payment
- $175 million
- Later installments
- $145.4 million (two $72.7M payments due Jan 31, 2027 and Apr 30, 2027)
- Cash and equivalents
- 396100000
- Settlement total net
- $380.7 million
- Antitrust related payment
- $60.3 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.